---

Use of 25 MCG for early induction of labour in active management of labour –Study of 100 cases in private setup

---

Original Article

Author Details : Manish R Pandya*, Kalpana Khandheriya, Rina Thakor, Jeel Modesara, Khushbu Patel

Volume : 8, Issue : 1, Year : 2021

Article Page : 31-34

https://doi.org/10.18231/j.ijogr.2021.006

Suggest article by email

Get Permission

---

Abstract

Background: Induced labour is one in which pregnancy is terminated artificially, any time after fetal viability is attained by a method that aims to secure vaginal delivery. It is one of the important procedures in obstetrics. The key factor for a successful induction is the cervical status, consistency and dilatation which is determined by the Bishop’s score. Prostaglandins are more effective in cases of unfavourable cervix or in the pregnancies remote from the term. Misoprostol, a prostaglandin E1 analogue is relatively inexpensive, can be easily stored at room temperature and has fewer systemic adverse effects. 1 It has rapid absorption
both orally and vaginally.
Objective: To determine the efficacy and safety of vaginally administered misoprostol for third trimester cervical ripening or induction of labour in a study conducted on 100 patients in Mahaveer Hospital, Scientific Research Institute, Surendranagar, Gujarat.
Materials and Methods: This was prospective study conducted in private setup from October 2020 to February 2021. Study population comprised of 100 subsequent pregnant women who required induction of labour were recruited after applying inclusion and exclusion criteria. The progress of labour was charted on the partograph. The mean induction delivery interval, mode of delivery, maternal and neonatal outcome and complications were observed.

Keywords: Induction of labour, Misoprostol, Vaginal route, Oxytocin.

How to cite : Pandya M R , Khandheriya K , Thakor R , Modesara J , Patel K , Use of 25 MCG for early induction of labour in active management of labour –Study of 100 cases in private setup. Indian J Obstet Gynecol Res 2021;8(1):31-34

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.